Clinical Trial Update: Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis [Phase 3]

View source ↗

Summary

Phase 3 trial update on efficacy and safety of peginterferon beta-1a (CinnaGen) in relapsing remitting multiple sclerosis showed results after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Peginterferon beta-1a (peginterferon beta-1a)

Snippet

Sponsor: Cinnagen | Conditions: Relapsing Remitting Multiple Sclerosis (RRMS) | Phase 3 | Status: COMPLETED